Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (129,492)	$ (4,270)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	157	94
Amortization of right-of-use asset	106	54
Accretion of discount related to marketable securities	(538)
Share-based compensation expense	2,159	1,224
Charge for purchase of in-process research and development assets	111,954
Changes in operating assets and liabilities:
Prepaid expenses and other assets	2,473	214
Accounts payable	2,396	687
Accrued expenses and other current liabilities	669	(1,404)
Deferred revenue	(1,029)	27,636
Operating lease liabilities	(25)	(62)
Net cash (used in) provided by operating activities	(11,170)	24,173
Cash flows from investing activities:
Cash paid in connection with Ayala asset acquisition	(20,060)
Cash paid in connection with Zentalis license agreement	(15,007)
Purchases of property and equipment	(2,164)	(106)
Net cash used in investing activities	(37,231)	(106)
Cash flows from financing activities:
Proceeds from public offering	230,002
Payment of offering costs	(14,155)
Proceeds from exercise of stock options	171
Proceeds from exercise of common stock warrants	3,427
Proceeds from issuance of common stock under ATM, net		34
Net cash provided by financing activities	219,445	34
Net increase in cash and cash equivalents and restricted cash	171,044	24,101
Cash and cash equivalents and restricted cash at beginning of period	98,779	20,423
Cash and cash equivalents and restricted cash at end of period	269,823	44,524
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	269,723	44,424
Restricted cash	100	100
Total cash, cash equivalents, and restricted cash	269,823	44,524
Supplemental disclosures of non-cash investing and financing activities:
Issuance of common stock in exchange for in-process research and development	74,033
Liabilities assumed in Ayala asset acquisition	2,041
Purchase of in-process research and development assets in accounts payable	813
Public offering costs included in accounts payable	437
Issuance of common stock to certain board of directors in lieu of accrued compensation		221
Purchases of property and equipment in accounts payable	$ 594	$ 223